6:42 PM · 24 February 2022

Moderna stock surges after upbeat quarterly results

Moderna
Stocks
MRNA.US, Moderna Inc
-
-

Moderna (MRNA.US) stock rose over 10% during today's session after the vaccine maker reported solid quarterly results. 

  • The biotech company earned an adjusted $11.29 per share on $7.2 billion of revenue, easily beating market expectations of  $9.90 in earnings per share on $6.78 billion of revenue. 
  • The company’s CEO told CNBC that he thought people would need another Covid booster shot in the fall.
  • Modeerna expects at least $19 billion ofcoronavirus vaccine - Spikevax sales in 2022, with additional signed options of approximately $3 billion.
  • Company unveiled a new $3 billion share repurchase plan.

Moderna (MRNA.US) stock fell sharply in recent months, however it seems that buyers managed to halt declines around $149.60 level which coincides with 78.6% Fibonacci retracement of the upward wave launched at the beginning of 2020 and 50 SMA (green line). As long as the price sits above this level, upward move may be resumed. On the other hand, if sellers manage to regain control, then another downward impulse towards support at $56.55 may be launched. Source: xStation5

21 October 2025, 10:04 AM

What to expect from Coca-Cola's third quarter 2025 results?

20 October 2025, 2:44 PM

IBM and Groq join forces to revolutionize AI processing

20 October 2025, 2:41 PM

US Defense Industry Preview - Has it reached its peak?

20 October 2025, 12:16 PM

Waymo: Race against the regulators

Join over 1 700 000 XTB Group Clients from around the world

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits